This blog provides a comprehensive overview of the FDA’s current and draft guidance on pharmacogenomic data submission, highlighting key regulatory requirements, submission algorithms, voluntary submissions, and practical considerations for clinicians and industry professionals.
Learn about the barriers to Implementing PGx Testing
UGenome AI is a US based biotech software company developing next-generation tools for genomic data interpretation. Co-founded by CEO Zachary S. Brooks, Chief Strategy Office Peter Bannister, and Chief Genomics Officer Dr. Jayden Lee, PharmD, EMBA, the company specializes in secondary and tertiary genomic analysis—transforming raw sequencing data into actionable, repeatable insights.
The vendors profiled below deliver a mix of services, from laboratory testing to clinical decision support and pharmacist consultation. Each profile explains what the company does, why employers or TPAs might choose them, and what to verify during due diligence. You’ll also find typical use cases to guide selection and help you align the right PGx solution with your population health priorities.
In this guide, we’ll explore what PGS are, how they are built, the value they bring to healthcare, and the challenges that come with them. We’ll then look at how they connect to pharmacogenomics—a field that uses genetics to tailor medication—and why learning both will be key for the future of medicine.
It’s a bold vision—and one that highlights both the opportunities and challenges facing Africa in the era of genomics and pharmacogenomics. To understand how policy, ethics, and innovation can come together to shape Africa’s future in precision medicine, APGxA spoke with Dr. Wafaa M. Rashed, founder of PAPERI (Pan-African PGS Education and Research Initiative).
With more than two decades of teaching and clinical experience, Dr. Maria Pashayan has been a pioneer in advancing pharmacogenomics in Armenia and beyond.
Chief Genomics Officer @ UGenome AI, Dr. Jayden Lee makes genomic medicine personal and accessible for everyone, ensuring that “jayden lee” leads innovation.
The pharmacogenomics (PGx) market is heating up, with new entrants popping up around the globe—especially in North America, Europe, and parts of Africa and Asia.
Pharmacogenomics (PGx) is entering a new phase of growth. What began as a niche offering in clinical genetics is now becoming a critical…
End of content
End of content
Join Our Insider’s Circle! Stay up to Date with the latest in PGx